Previous 10 | Next 10 |
Plus Therapeutics is a clinical-stage biotech focused on radiotherapeutics for patients with rare and difficult to treat cancers. CEO Dr. Marc Hedrick on Rhenium-186 NanoLiposome, clinical trials and its niche focus. Lean business model means less dilution. For further detai...
AUSTIN, Texas, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hed...
Announcing interim results from the first-in-human trial for its lead candidate Rhenium-186 NanoLiposome, Plus Therapeutics (NASDAQ:PSTV) said the drug was well tolerated with no dose-limiting toxicities in the study involving patients with recurrent glioblastoma (GBM). Rhenium-186 NanoL...
Latest interim analysis shows Rhenium-186 NanoLiposome ( 186 RNL) well-tolerated without dose-limiting toxicities Mean and median overall survival in patients receiving absorbed dose greater than 100 Gy is 453.8 days and 330 days, respectively, with seven patients rema...
AUSTIN, Texas, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that on November...
AUSTIN, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the U.S. Fo...
Company Management and Principal Investigators to Discuss Trial Data Webinar Scheduled for Thursday, November 18, 2021 at 4:00 - 5:00 p.m. ET AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a c...
Data demonstrated Rhenium-186 NanoLiposome ( 186 RNL) provides sustained, localized radiation treatment for over eight days to the tumor with minimal whole brain and body radiation exposure The analysis of 3D drug distribution and tumor response shows image monitorin...
Plus Therapeutics, Inc. (PSTV) Q3 2021 Earnings Conference Call October 21, 2021, 05:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Financial Officer Conference Call Participants Jason Mccarthy - Maximum Group Ed Woo - Ascendiant Capital...
AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial result...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...